A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of Pulsed GRF6019 Infusions in Subjects With Severe Alzheimer's Disease

This study will evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment GRF6019 in subjects with severe Alzheimer's disease.

开始日期2019-01-15

申办/合作机构

Alkahest, Inc.初创企业

NCT03520998

/ Completed临床2期

A Prospective, Randomized, Double-Blind, Dose-Comparison Concurrent Control Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease

This study is evaluating the safety, tolerability, and feasibility of GRF6019, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with mild to moderate Alzheimer's disease.

开始日期2018-04-16

申办/合作机构

Alkahest, Inc.初创企业

100 项与 GRF-6019 相关的临床结果

登录后查看更多信息

100 项与 GRF-6019 相关的转化医学

登录后查看更多信息

100 项与 GRF-6019 相关的专利（医药）

登录后查看更多信息

项与 GRF-6019 相关的文献（医药）

2021-06-15·Journal of Alzheimer's Disease3区 · 医学

Safety and Tolerability of GRF6019 Infusions in Severe Alzheimer’s Disease: A Phase II Double-Blind Placebo-Controlled Trial

3区 · 医学

Article

作者: Nikolich, Karoly ; Albensi, Benedict ; Koborsi, Katie ; Cummings, Jeffrey L. ; Thein, Stephen G. ; Duclos, Tiffanie ; Scott, James ; Chao, Whitney ; Braithwaite, Steven ; Patel, Ashok K. ; Kay, Gary ; Hannestad, Jonas ; Klutzaritz, Vicki ; Beck, Brian

Background: The plasma fraction GRF6019 shows multiple benefits on brain aging in mice, including enhanced cognition, neurogenesis, and synaptic density, as well as reduced neuroinflammation. Objective: To evaluate the safety, tolerability, and preliminary efficacy of GRF6019 in patients with severe Alzheimer’s disease (AD). Methods: A phase II, double-blind, placebo-controlled study in patients with severe AD (Mini-Mental State Examination score 0–10). Patients were randomized 2 : 1 to GRF6019 (N = 18) or placebo (N = 8) and received daily 250 mL intravenous infusions over 5 days. The primary endpoints were the rates of adverse events (AEs) and the tolerability of GRF6019 as assessed by the number of patients completing the study. Change from baseline in cognitive and functional assessments was also evaluated. Results: All patients completed 100%of study visits and infusions. The rate of AEs was similar in the GRF6019 (8/18 patients [44.4%]) and placebo (3/8 patients [37.5%]) groups, and there were no deaths or serious AEs. The most common AEs considered related to treatment were mild, transient changes in blood pressure in the GRF6019 group (hypotension: 2 patients [11.1%]; hypertension: 1 patient [5.6%]); there were no related AEs in the placebo group. The trial was not powered to detect statistically significant differences between treatment groups. At the end of the study, patients in both treatment groups remained stable or improved on all cognitive and functional endpoints. Conclusion: GRF6019 demonstrated excellent safety, feasibility, and tolerability. Future trials designed to characterize the potential functional benefits of GRF6019 and related plasma fractions in severe AD are warranted.

2020-01-01·Alzheimer's & Dementia: Translational Research & Clinical Interventions

Safety and tolerability of GRF6019 in mild‐to‐moderate Alzheimer's disease dementia

Article

作者: Páez, Antonio ; Jackson, Sam ; Hannestad, Jonas ; Nikolich, Karoly ; Ray, Rebecca ; Klutzaritz, Vicki ; Kay, Gary ; Koborsi, Katie ; Chao, Whitney ; Braithwaite, Steven ; Cummings, Jeffrey L. ; Lohr, Scott

AbstractIntroductionThis phase 2 trial evaluated the safety, tolerability, and feasibility of repeated infusions of the plasma fraction GRF6019 in mild‐to‐moderate Alzheimer's disease.MethodsIn this randomized, double‐blind, dose‐comparison trial, 47 patients were randomized 1:1 to receive daily infusions of 100 mL (n = 24) or 250 mL (n = 23) of GRF6019 for 5 consecutive days over two dosing periods separated by a treatment‐free interval of 3 months.ResultsThe mean (standard deviation [SD]) age of the enrolled patients was 74.3 (6.9), and 62% were women. Most adverse events (55%) were mild, with no clinically significant differences in safety or tolerability between the two dose levels. The mean (SD) baseline Mini‐Mental State Examination score was 20.6 (3.7) in the 100 mL group and 19.6 (3.7) in the 250 mL group; at 24 weeks, the within‐patient mean change from baseline was –1.0 points (95% confidence interval [CI], –3.1 to 1.1) in the 100 mL group and +1.5 points (95% CI, –0.4 to 3.3) in the 250 mL group. The within‐patient mean change from baseline on the Alzheimer's Disease Assessment Scale‐Cognitive subscale was –0.4 points (95% CI, –2.9 to 2.2) in the 100 mL group, while in the 250 mL group it was –0.9 points (95% CI, –3.0 to 1.2). The within‐patient mean change from baseline on the Alzheimer's Disease Cooperative Study‐Activities of Daily Living was –0.7 points in the 100 mL group (95% CI, –4.3 to 3.0) and –1.3 points (95% CI, –3.4 to 0.7) in the 250 mL group. The mean change from baseline on the Category Fluency Test, Clinical Dementia Rating Scale–Sum of Boxes, Alzheimer's Disease Cooperative Study–Clinical Global Impression of Change, and Neuropsychiatric Inventory Questionnaire was similar for both treatment groups and did not show any worsening.DiscussionGRF6019 was safe and well tolerated, and patients experienced no cognitive decline and minimal functional decline. These results support further development of GRF6019.

项与 GRF-6019 相关的新闻（医药）

2021-02-03

·BioSpace

Clinical Catch-Up: January 25-29

It was a busy week for clinical trial news. Read on for more information. COVID-19-Related Johnson & Johnson announced topline efficacy and safety data from the Phase III ENSEMBLE trial of its single-dose COVID-19 vaccine in development by Janssen Pharmaceutical Companies. It met all primary and key secondary endpoints. The data suggested the vaccine was 66% effective overall in preventing moderate to severe COVID-19, 28 days after vaccination, with protection observed as early as day 14. There were variations in country-to-country studies against moderate to severe COVID-19 infection 28 days after vaccination: U.S. (72%); Latin America (66%); South Africa (57%). Against severe disease, it was 85% effective in all regions 28 days after vaccination, with efficacy increasing over time with no cases reported after day 49. It demonstrated complete protection against COVID-19-related hospitalization and death, 28 days after vaccination. Merck announced that it was going to stop developing its two COVID-19 vaccine candidates, dubbed V590 and V591, after poor responses in the Phase I trials. They are shifting their attention to advancing two therapeutic drugs for COVID-19, MK-4482 and MK-7110. Merck is developing MK-4482 with Ridgeback Biotherapeutics. In the Phase I trials, V590 and V591 were generally well tolerated, but the company reports that immune responses were inferior to what was observed in people who recovered naturally from COVID-19 infections. Eli Lilly and Company announced the results of its Phase III BLAZE-2 COVID-19 prevention trial, conducted with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and the COVID-19 Prevention Network (CoVPN). The trial evaluated the company’s bamlanivimab (LY-COV555), its neutralizing antibody, in COVID-19 in residents and staff at nursing homes in the U.S. At eight weeks of follow-up, there was a significantly lower frequency of symptomatic COVID-19 in the bamlanivimab treatment arm compared to placebo. Eli Lilly’s bamlanivimab and esesivimab together significantly decreased COVID-19-related hospitalizations, hitting the primary endpoint of the Phase III BLAZE-1 trial. Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody directed against the COVID-19 virus spike protein. Etesevimabis a recombinant fully human monoclonal neutralizing antibody that specifically binds to the SARS-CoV-2 surface spike protein receptor binding domain with high affinity and can block the binding of the virus to the ACE2 host cell surface receptor. Achiko AG and Regenacellx.sl announced the completion of their Phase I trial of its nanoparticulate DNA aptamer conjugate and diagnostic testing technology, Project Gumnuts. The COVID-19 testing study demonstrated in field tests 80% sensitivity and 63% specificity. Applying software and machine learning increased it to 91% sensitivity and 85% specificity. Regeneron Pharmaceuticals announced positive initial data from its ongoing Phase III trial of its antibody cocktail, REGEN-COV, as a passive vaccine to prevent COVID-19 in people at high risk of infection from household exposure. The trial is being run with NIAID. Exploratory analysis found that the cocktail demonstrated 100% prevention of symptomatic infection in the 400 patients that could be evaluated. There was also about a 50% lower overall rate of infection, symptomatic and asymptomatic. The lower number of infections in the group on the cocktail were all asymptomatic, with decreased peak virus levels and a short duration of viral shedding, suggesting they were less likely to spread the disease. Vir Biotechnology, Eli Lilly and GlaxoSmithKline inked a three-way deal to evaluate Vir’s monoclonal antibody, VIR-7831, in combination with Lilly’s bamlanivimab in low-risk mild to moderate COVID-19 patients. Lilly expanded its ongoing BLAZE-4 study to include Vir’s compound. Vir and GSK were already partnered on the development of VIR-7831. Dr. Reddy's Laboratories and Global Response Aid FZCO terminated its Avigan Trial Study in Kuwait focused on moderate to severe COVID-19 patients in a hospital setting. The Phase III study in outpatient setting in North America in partnership with Appili Therapeutics and Global Response Aid will continue. The Kuwait study did not show a statistically significant difference for the primary endpoint for Avigan compared to placebo. Avigan (favipiravir) is an antiviral drug marketed by Fujifilm Toyota Chemical Co. Valneva completed enrollment in its Phase I/II trial of its COVID-19 vaccine candidate. VLA2001 is an inactivated vaccine candidate, meaning it uses an inactivated SARS-CoV-2 virus with an adjuvant to further stimulate the immune system. Initial data is expected in April. EmitBio announced that its clinical trial of EmitBIo device achieved a 99.9% reduction in average viral load of SARS-CoV-2 and accelerated time to symptom resolution by more than 48 hours compared to the control group. The device uses a small handheld device that directs precise wavelengths of safe, visible, targeted light to the back of the throat and surrounding tissues. Novavax reported that NVX-CoV2373, its COVID-19 vaccine, demonstrated an efficacy of 89.3% in its Phase III trial in the UK. It also announced positive data from its Phase IIb trial in South Africa. Non-COVID-19-Related Roche announced topline data from two identical Phase III trials, TENAYA and LUCERNE, of faricimab in neovascular or “wet” age-related macular degeneration (nAMD). Both trials hit their primary endpoint, demonstrating visual acuity outcomes that were non-inferior to aflibercept injections. They received faricimab injections at fixed intervals up to every 16 weeks compared to every eight weeks for aflibercept. Aflibercept is marketed by Regeneron Pharmaceuticals as Eylea. Faricimab is a bispecific antibody, meaning it is designed to recognize two different antigens. In this case, it targets angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), both of which are associated with several diseases of the retina. Abeona Therapeutics announced it held a successful Type B meeting with the FDA over its co-primary endpoints for the pivotal Phase III VIITAL trial of EB-101 in recessive dystrophic epidermolysis bullosa (RDEB). The drug is an autologous, gene-corrected cell therapy. RDEB is a rare connective tissue disorder with no approved therapies. Vir Biotechnology announced initial topline data from its ongoing Phase I trial of VIR-3434 in chronic hepatitis B virus (HBV) infection. The early data demonstrated a mean reduction in serum hepatitis B virus surface antigen by day eight. VIRI-3434 is an HBV-neutralizing monoclonal antibody designed to block entry of all 10 genotypes of HBV into hepatocytes and decrease the level of viral and subviral particles in the blood. Rhythm Pharmaceuticals announced positive proof-of-concept data from multiple cohorts in its Phase II Basket Study of setmelanotide in patients with severe obesity due to genetic variants in the melanocortin-4 receptor (MC4R) pathway. Setmelanotide (Imcivree) is indicated for chronic weight management in adults and children age six years and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilism/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. Exilixis initiated the first-in-human Phase I trial of XL1-2 alone or in combination with other therapies in patients with inoperable locally advanced or metastatic solid tumors. XL102 is a potent, selective and orally bioavailable inhibitor of cyclin-dependent kinase 7 (CDK7). Pfizer announced co-primary endpoint data from a recently wrapped post-market safety study of tofacitinib at two doses compared to a TNF inhibitor in patients with rheumatoid arthritis who were 50 years of age or older with at least one additional cardiovascular risk factor. The co-primary endpoints were non-inferiority of tofacitinib compared to TNFi in relation to major adverse cardiovascular events (MACE) and malignancies (excluding non-melanoma skin cancer (NMSC). The non-inferiority criteria were not met for the endpoints, with no evidence of a difference between the two tofacitinib treatment groups. Agios Pharmaceuticals reported its Phase III ACTIVATE-T trial of mitapivat in regularly transfused adults with PK deficiency demonstrated a statistically significant and clinically meaningful decrease in transfusion burden. Mitapivat is a first-in-class oral, small molecule allosteric activator of wild-type and a variety of mutated PKR enzymes. NervGen Pharma Corp announced it was adding an Alzheimer’s disease patient cohort to its Phase I trial of NVG-291. The Phase I program was originally going to be in healthy volunteers. The drug is a specific and selective protein tyrosine phosphatase sigma inhibitor. EyePoint Pharmaceuticals dosed the first patient in its Phase I trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment for wet age-related macular degeneration (wet AMD). The drug uses the company’s Durasert drug delivery technology that is already approved in four FDA-approved products. Organicell Regenerative Medicine announced the FDA had approved its IND for Zofin in COPD. The approved Phase I/II clinical trial will evaluate the safety and efficacy of IV Zofin for COPD. Zofin is an acellular, biologic derived from perinatal sources and is engineered to retain naturally occurring microRNAs. Takeda Pharmaceutical announced new data from the Phase I/II trial of TAK-788 (mobocertinib) in previously treated patients with EGFR Exon20 insertion+ metastatic non-small cell lung cancer (mNSCLC). The data showed the drug resulted in clinically meaningful responses and a “noteworthy” duration of response in this patient population. Mobocertinib is an oral tyrosine kinase inhibitor (TKI) designed to target EGFR Exon20 insertion mutations. Alklahest published data from its Phase II trial of GRF6019 for Alzheimer’s disease. It met the primary endpoint, showing both dose levels were safe and well tolerated. Patients also demonstrated a lack of cognitive decline and limited functional decline over the 24-week study period. The drug is a proprietary plasma fraction that has enhanced neurogenesis and improved age-related deficient in learning and memory, as well as decreased neuroinflammation in preclinical animal studies. Orion Biotechnology Canada presented results from their Phase I trial of OB-002H at the HIVR4P virtual meeting. It evaluated OB-002h Gel for prevention of HIV. OB-002 is a CCR5 inhibitor with best-in-class in vitro potency and is also being studied in oncology and COVID-19. Amgen announced results from the Phase II cohort of the CodeBreaK 100 trial of sotorasib in 126 patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). The drug demonstrated a confirmed objective response rate (ORR) and disease control rate (DCR) of 37.1% and 80.6%, respectively, and a median duration of response of 10 months. Sotorasib is an investigational KRASG12C inhibitor. Janssen Pharmaceutical Companies, of J&J, announced new data from the Phase I CHRYSALIS trial of amivantamab in metastatic or unresectable non-small cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations whose disease progressed on or after platinum-based chemotherapy. The drug is an investigational, fully-human EGFR and MET bispecific antibody. The findings demonstrated robust activity and durable responses. Most Read Today

疫苗抗体First in Class细胞疗法小分子药物

2021-01-28

·BioSpace

Alkahest Announces Peer-Reviewed Publication Demonstrating Safety and Tolerability of GRF6019 in Patients with Mild-to-Moderate Alzheimer’s Disease

GRF6019 was safe and well-tolerated, and patients experienced no cognitive decline and minimal functional decline SAN CARLOS, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced the publication of a peer-reviewed article in the journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions. The publication titled, “Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer’s disease dementia,” describes Alkahest’s Phase 2 clinical trial investigating GRF6019 as a potential treatment for patients with Alzheimer’s disease (AD) and is available online here. “With a rapidly growing elderly population, the rates of chronic age-related diseases are on track to skyrocket in the coming years,” said Karoly Nikolich, chief executive officer and co-founder of Alkahest. “The publication of GRF6019’s safety and tolerability data in Alzheimer’s and Dementia reflects the potential of Alkahest’s novel approach to tackle Alzheimer’s disease, an indication that has seen little meaningful clinical progress in the past few decades. We look forward to further studying its potential as a more effective therapeutic option for this drastically underserved patient population.” Study highlights: The trial met its primary endpoint, demonstrating that both dose levels were safe and well tolerated, with no clear difference in adverse events between the 100 and the 250 milliliter dose arms. Patients treated with GRF6019 showed a lack of cognitive decline and limited functional decline over the 24-week study period. Alkahest is studying GRF6019 as a potential treatment for age-related diseases in collaboration with clinical development partner and parent company, Grifols. GRF6019 is a proprietary plasma fraction that has enhanced neurogenesis, improved age-related deficits in learning and memory and reduced neuroinflammation in preclinical animal models. Having completed human studies with GRF6019 in patients with both mild-to-moderate and severe Alzheimer’s disease, Alkahest plans to advance GRF6019 to further study its efficacy in these patient populations. About ALK6019-201 The Phase 2a ALK6019-201 trial was designed to evaluate the safety, tolerability, and potential therapeutic effects of two doses of GRF6019 in patients with mild-to-moderate Alzheimer’s disease over six months. Subjects were randomized to receive either 100 mL or 250 mL of GRF6019 given by intravenous administration daily for five consecutive days during week 1 and again for five consecutive days during week 13, with a treatment-free interval of 11 weeks following each dose. About Grifols Grifols is a global healthcare company that since its founding in Barcelona in 1909 has enhanced the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services in more than 100 countries. As pioneers in the plasma industry, Grifols is one of the largest plasma companies, with a growing network of donation centers worldwide. It develops this plasma into essential medicines used to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation through transfusion. And the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care. Grifols, with more than 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. In 2019, Grifols’ economic impact in its core countries of operation was 8.5 billion euros. The company also generated 148,000 jobs, including indirect and induced. The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). Alkahest is a clinical stage biopharmaceutical company dedicated to discovering and developing treatments for neurodegenerative and age-related diseases with transformative therapies targeting the aging plasma proteome. The Alkahest pipeline includes multiple therapeutic candidates ranging from selected plasma fractions to protein-targeted interventions which aim to slow the detrimental biological processes of aging. For more information, please visit or . Media Contact Michael Tattory LifeSci Communications 1 (646) 751-4362 mtattory@lifescicomms.com

合作

2018-07-23

·alkahest.com

Alkahest to Present at Alzheimer’s Association International Conference (AAIC) Annual Meeting July 22-26, 2018 Chicago, IL

Presentations highlight a novel multifactorial approach to the treatment of Alzheimer’s Disease SAN CARLOS, Calif., — Alkahest Inc. (“Alkahest”), a clinical-stage biotechnology company focused on developing innovative therapies to treat Alzheimer’s Disease and other age-related diseases, today announced upcoming presentations at the Alzheimer’s Association International Conference in Chicago, July 22 to 26, 2018. The Alkahest team will present recent preclinical data and clinical trial designs for the company’s novel approaches to the treatment of Alzheimer’s Disease. Details for specific presentations are: Beneficial Properties of a Human Plasma Fraction for Age-Related Cognitive Disorders (Gallager, July 23, F1/P2-064) Rationale and Design of a Prospective, Randomized, Double-Blind, Dose-Comparison Safety and Tolerability Study of GRF6019 in Mild-to-Moderate Alzheimer’s Disease (Hannestad, July 23, F1/P2-029) Targeting the Eotaxin/CCR3 Pathway in Aging-Associated Cognitive Decline (Minami, July 24, F1/P3-043) CCR3 Antagonism Drives Neuroinflammatory Benefits in Aged Mice (Rege, July 24, F1/P3-051) “These presentations and findings add to the growing body of research supporting our hypothesis that factors in the plasma proteome play an important modulatory role in age-related disease, particularly cognitive dysfunction and neurodegeneration. This presents an entirely new opportunity for therapeutic interventions,” said Karoly Nikolich, Ph.D., Chief Executive Officer of Alkahest. “As the world’s population grows older, the burden of age-related diseases will quickly become one of the greatest medical challenges of our generation. Our innovative therapeutics targeting the plasma proteome are currently in clinical development and are well-positioned to address this critical need,” said Jonas Hannestad, M.D., Ph.D., Alkahest’s Vice President, Clinical Development. Alkahest is a privately-held clinical-stage company based in the San Francisco Bay Area developing treatments for age-related diseases, with an emphasis on neurodegeneration — a key medical challenge for our generation. The company’s breakthrough research has elucidated changes in the plasma proteome in healthy aging and age-related diseases, and demonstrated that factors in the blood plasma can be augmented or inhibited in order to reverse detrimental effects of aging in both normal aging and disease models in animals. Alkahest is developing novel plasma-based therapies in collaboration with Barcelona, Spain-based Grifols, a global healthcare company and leading producer of plasma therapies. Contact Information Joe McCracken Vice President Business Development Alkahest, Inc. jmccracken@alkahest.com

100 项与 GRF-6019 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床2期	美国	Alkahest, Inc.初创企业	2018-04-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AAIC2022	N/A	阿尔茨海默症	-	GRF6019 100 mL	淵餘獵遞繭廠憲鏇鬱壓(鹽構淵範獵範獵顧糧積) = 壓獵廠廠膚餘襯蓋襯網構憲夢糧糧壓遞遞窪鹽 (製憲願醖願憲願構壓夢, > 0.05) 更多	-	2022-02-01
				GRF6019 250 mL	淵餘獵遞繭廠憲鏇鬱壓(鹽構淵範獵範獵顧糧積) = 壓夢繭鏇鹹觸膚壓壓遞構憲夢糧糧壓遞遞窪鹽 (製憲願醖願憲願構壓夢, > 0.05) 更多
NCT03765762 (CTgov)	临床2期	阿尔茨海默症	26	GRF6019 (GRF6019)	壓範繭糧製膚蓋積願鹹(餘夢鏇選選鹹範選獵鏇) = 醖餘鑰憲窪夢夢憲觸獵蓋壓衊蓋壓簾醖鏇繭積 (衊製壓簾選築膚築糧餘, 艱積觸鏇製簾願鹹鏇觸 ~ 選醖範餘繭糧蓋鹹夢遞) 更多	-	2021-01-27
				Placebo (Placebo)	壓範繭糧製膚蓋積願鹹(餘夢鏇選選鹹範選獵鏇) = 鹹糧艱繭膚簾顧鬱觸襯蓋壓衊蓋壓簾醖鏇繭積 (衊製壓簾選築膚築糧餘, 積選築遞顧範顧選膚窪 ~ 醖鹽窪簾襯獵鑰觸構蓋) 更多
NCT03520998 (Pubmed) 人工标引	临床2期	阿尔茨海默症	47	GRF6019 (100 mL)	(憲簾衊餘鹽範網襯鏇襯) = 製願觸獵鹹鬱淵鑰夢衊淵淵簾衊齋蓋淵顧夢艱 (衊齋憲憲廠蓋艱觸簾鏇, -2.9 ~ 2.2) 更多	积极	2020-12-16
				GRF6019 (250 mL)	(憲簾衊餘鹽範網襯鏇襯) = 艱窪餘鬱淵膚簾夢鹹衊淵淵簾衊齋蓋淵顧夢艱 (衊齋憲憲廠蓋艱觸簾鏇, -3.0 ~ 1.2) 更多
NCT03520998 (CTgov)	临床2期	阿尔茨海默症	47	GRF6019 (GRF6019 Low Dose)	鑰鏇膚膚獵壓窪艱鏇鹽(齋簾鹹醖獵築鹹簾憲網) = 壓襯襯築鹹糧餘獵獵獵艱鬱夢鬱窪簾鑰製願鹽 (廠願簾鑰醖廠築構廠遞, 繭鹽積艱壓餘衊鹽願衊 ~ 觸範衊夢糧範簾窪簾選) 更多	-	2020-11-05
				GRF6019 (GRF6019 High Dose)	鑰鏇膚膚獵壓窪艱鏇鹽(齋簾鹹醖獵築鹹簾憲網) = 觸淵糧遞齋構範衊壓鬱艱鬱夢鬱窪簾鑰製願鹽 (廠願簾鑰醖廠築構廠遞, 齋襯選鏇鬱鬱衊蓋廠鏇 ~ 構糧鏇遞願顧觸繭艱鹹) 更多